Cancer Biomarkers Market
Buy Now Request Sample Explore
Home › Report Store › Life Sciences  › Cancer Biomarkers Market

Cancer Biomarkers Market Outlook: Size, Share, Trends, Growth Analysis, Competitive Landscape & Forecast, 2026-2033

The Cancer Biomarkers Market size was valued at US$ 28.15 billion in 2025 and is projected to reach US$ 98.05 billion by 2033, growing at a CAGR of 16.88% during 2026–2033. Growth is driven by rising cancer prevalence, precision oncology adoption, advancing molecular diagnostics, liquid biopsy expansion, AI-assisted biomarker discovery, and increasing demand for targeted therapies.

Report Coverage
  • Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others
  • Biomarker Type: PSA, HER-2, EGFR, KRAS, Others
  • End User: Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, Others
US$ 28.15 Bn Market size in 2025
US$ 98.05 Bn Market Size by 2033
16.88% CAGR, 2026 - 2033
2026-2033 Forecast Period
01 AI Overview

Cancer Biomarkers Market Summary

  • North America Region: North America holds an estimated 42%–46% share in 2025, growing at a 16.2%–16.9% CAGR during 2026–2033. Strong oncology research infrastructure, advanced diagnostic adoption, precision medicine investments, and pharmaceutical innovation support regional growth. The US market remains the dominant contributor, expanding at an estimated 16.4%–17.1% CAGR through 2033 due to clinical research activity and advanced molecular testing adoption.
  • Fastest Growing Region: Asia Pacific represents an estimated 22%–26% share in 2025, expanding at a 17.5%–18.4% CAGR during 2026–2033. Rising cancer burden, improving healthcare infrastructure, biotechnology investments, and increasing access to molecular diagnostics accelerate regional market expansion during cancer biomarkers market forecasts.
  • Leading Segment: Breast Cancer biomarkers account for an estimated 28%–32% share in 2025, growing at a 16.0%–16.8% CAGR during 2026–2033. High disease prevalence, extensive biomarker research, HER-2 testing adoption, and targeted treatment development support segment leadership.
  • High Growth Segment: Liquid biopsy-related biomarker applications represent an estimated 18%–22% share in 2025, expanding at a 18.5%–19.5% CAGR during 2026–2033. Non-invasive testing advantages, early detection potential, and technological advancements in circulating tumor DNA analysis support rapid adoption.
  • Key Market Opportunity: Liquid biopsy expansion, AI-driven biomarker identification, companion diagnostics development, and personalized cancer treatment approaches are creating significant opportunities for diagnostics companies, research organizations, and pharmaceutical developers.
  • Major Market Players: F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, Siemens Healthineers AG, Becton, Dickinson and Company.
02 Strategic Insights

Cancer Biomarkers Market: Strategic Insights

cancer-biomarkers-market-market-strategic-framework
FREE PDF
Request your free sample
Request free sample
03 Stakeholder View

Key Takeaways

  • The Cancer Biomarkers market ecosystem includes diagnostic companies, biotechnology firms, pharmaceutical developers, research laboratories, hospitals, and technology providers, with collaboration between stakeholders becoming essential for biomarker validation and commercialization.
  • Precision oncology represents the largest strategic opportunity as healthcare providers increasingly use molecular information to guide targeted therapies, improve treatment outcomes, and reduce ineffective treatment approaches.
  • Innovation is accelerating around liquid biopsy platforms, artificial intelligence-based biomarker discovery, multi-omics analysis, and next-generation sequencing technologies that improve cancer detection and monitoring.
  • North America remains a high-value investment region due to advanced healthcare infrastructure, strong research funding, established biotechnology clusters, and rapid adoption of precision medicine solutions.
  • Strategic partnerships, acquisitions, and collaborations between diagnostic companies and pharmaceutical firms are increasing as companies seek integrated companion diagnostic capabilities and expanded oncology portfolios.
  • Emerging markets provide long-term growth potential through improved healthcare access, increasing cancer screening initiatives, rising biotechnology investments, and expanding availability of advanced molecular diagnostic technologies.
04 Geographic Outlook

Cancer Biomarkers Market Regional Highlights

North America Cancer Biomarkers Market

North America accounts for an estimated 42%–46% share in 2025, supported by advanced healthcare systems, strong oncology research capabilities, and widespread adoption of molecular diagnostics. The region is projected to grow at a 16.2%–16.9% CAGR during 2026–2033. The US and Canada continue driving demand through precision oncology programs, pharmaceutical innovation, clinical research investments, and increasing use of biomarker-guided therapies.

  • The United States dominates regional demand due to extensive oncology research, advanced diagnostics infrastructure, and precision medicine adoption.
  • Pharmaceutical companies continue investing in biomarker-based drug development and companion diagnostic partnerships.
  • Healthcare providers are expanding molecular testing capabilities for personalized cancer treatment decisions.
  • Research institutions are advancing genomic studies supporting biomarker identification and validation.

US Cancer Biomarkers Market

The US represents an estimated 84%–88% North America's Cancer Biomarkers Market share in 2025 and is expected to expand at a 16.4%–17.1% CAGR through 2033. Growth is supported by high cancer research spending, advanced diagnostic infrastructure, biotechnology innovation, and increasing integration of biomarker testing into oncology workflows.

  • Precision oncology programs are increasing demand for genomic profiling and targeted biomarker testing.
  • Biotechnology companies are developing advanced diagnostic platforms for early cancer detection and monitoring.
  • Companion diagnostics adoption is expanding alongside targeted cancer therapies and immunotherapies.

Europe Cancer Biomarkers Market

Europe represents an estimated 26%–30% share in 2025, growing at a 16.0%–16.7% CAGR during 2026–2033. Strong healthcare systems, government-supported cancer research initiatives, and increasing adoption of personalized medicine support regional expansion. Germany, the United Kingdom, France, and Switzerland remain important contributors due to biotechnology capabilities and advanced diagnostic adoption.

  • Germany benefits from strong healthcare infrastructure and molecular diagnostics research capabilities.
  • The United Kingdom continues expanding precision oncology initiatives through research institutions and healthcare programs.
  • France supports biomarker adoption through cancer research networks and diagnostic technology investments.
  • Switzerland contributes through pharmaceutical innovation and biotechnology development.

Asia Pacific Cancer Biomarkers Market

Asia Pacific represents an estimated 22%–26% share in 2025 and records the fastest growth at a 17.5%–18.4% CAGR during 2026–2033. Increasing cancer prevalence, healthcare modernization, expanding diagnostic access, and biotechnology investments are supporting regional expansion. China, Japan, India, and South Korea are emerging as important markets due to growing research capabilities and healthcare investments.

  • China leads regional growth through biotechnology expansion, cancer research investments, and increasing diagnostic adoption.
  • Japan supports demand through advanced healthcare systems and precision medicine development.
  • India is expanding biomarker adoption through improving diagnostic infrastructure and oncology access.
  • South Korea is strengthening capabilities through biotechnology innovation and genomic research.
  • Regional governments are increasing investments in cancer screening and healthcare modernization.

Rest of World Cancer Biomarkers Market

Latin America, the Middle East, and Africa collectively represent an estimated 6%–9% share in 2025, expanding at a 15.8%–16.8% CAGR through 2033. Growth is supported by rising cancer awareness, improving healthcare infrastructure, increased diagnostic investments, and expanding access to advanced testing technologies. Brazil, Mexico, UAE, Saudi Arabia, and South Africa represent key developing markets.

  • Brazil is improving oncology diagnostics through healthcare investments and expanding laboratory capabilities.
  • Mexico is witnessing increasing adoption of advanced cancer testing technologies.
  • Middle Eastern countries are investing in specialized healthcare facilities and precision medicine programs.
  • South Africa is developing cancer diagnostic capabilities through healthcare modernization initiatives.
  • Emerging markets provide opportunities for affordable and scalable biomarker testing solutions.
global-market-geography
FREE PDF
Request your free sample
Request free sample
05 Segment Analysis

Cancer Biomarkers Market Segmentation

Cancer Type

The Cancer Type segment is the key demand driver of the Cancer Biomarkers Market, contributing about 82% to 86% of market revenue in 2025 and registering a 16.5% to 17.2% CAGR between 2026 and 2033. The rise in prevalence of cancer, increased understanding of tumor biology at a molecular level, and the use of targeted treatments are boosting the use of biomarkers in all important cancers. Biomarker tests have been increasingly integrated within the workflow of healthcare professionals for diagnosis, treatment, and monitoring of the disease. Advancements in genomic profiling and precision oncology continue expanding biomarker applications across diverse cancer types.

  • Breast Cancer: Breast cancer biomarkers maintain strong adoption due to high disease prevalence, HER-2 testing requirements, hormone receptor analysis, and increasing use of targeted treatment approaches.
  • Lung Cancer: Lung cancer biomarker demand is increasing through EGFR, ALK, and other molecular testing applications supporting personalized therapies and improved treatment decisions.
  • Colorectal Cancer: Colorectal cancer biomarkers are gaining importance through KRAS testing, molecular profiling, and targeted therapy selection for improved patient outcomes.
  • Prostate Cancer: Prostate cancer biomarker adoption is expanding through PSA testing advancements, molecular diagnostics, and improved monitoring strategies for disease progression.

Biomarker Type

The Biomarker Type segment is expected to account for approximately 76%-80% in 2025 and to register a CAGR of 16.8%-17.5% between 2026 and 2033. Molecular biomarkers are increasingly relevant owing to the shift towards personalized oncology treatment strategies. Drug manufacturers are incorporating biomarker testing into their clinical trials, while diagnostics companies are launching more accurate and rapid testing solutions, driving the cancer biomarkers market growth. The segment benefits from growing demand for companion diagnostics, genomic profiling, and biomarker-based treatment selection across multiple cancer indications.

  • PSA: PSA biomarkers remain widely used in prostate cancer screening, monitoring, and treatment evaluation due to established clinical adoption and diagnostic relevance.
  • HER-2: HER-2 biomarkers support targeted breast cancer therapies by identifying patients likely to benefit from HER-2-directed treatment strategies and personalized oncology approaches.
  • EGFR: EGFR biomarkers are increasingly utilized in lung cancer diagnostics to guide targeted therapies and improve treatment outcomes through molecular classification.
  • KRAS: KRAS biomarkers are important for colorectal cancer treatment decisions by identifying patients suitable for specific targeted therapeutic approaches.

End User

The End User segment is expected to account for 88%–92% of the market in 2025 and will continue to grow at a CAGR of 16.7%–17.4% through 2033. The use of biomarkers is on the rise among pharmaceutical firms, diagnostic labs, hospitals, and specialty clinics to enhance their ability to diagnose and treat cancer patients. The market growth is driven by expansion in precision oncology, ongoing clinical trials, and increasing involvement of molecular diagnostics in cancer care pathways, aligning with cancer biomarkers market trends.

  • Pharmaceutical & Biotechnology Companies: These companies utilize biomarkers for drug discovery, clinical trial patient selection, companion diagnostics development, and targeted oncology therapy advancement.
  • Diagnostics & Research Laboratories: Laboratories are expanding molecular testing capabilities through sequencing platforms, immunoassays, and advanced diagnostic technologies for cancer biomarker analysis.
  • Hospitals & Specialty Clinics: Hospitals and oncology centers increasingly adopt biomarker testing to support personalized treatment decisions and improve patient management.
06 Market Forces

Cancer Biomarkers Market Dynamics

Key Market Drivers

Rising cancer prevalence increases biomarker testing demand

The increasing incidence of cancer around the world will increase the need for reliable diagnostic and monitoring systems that can be performed using molecular biomarkers. The World Health Organization notes that cancer continues to be a major cause of death across the globe. As a result, there is a high need for health care due to the growing incidence of the disease. Using biomarker technology, doctors can determine the nature of the disease, its progression, and even the appropriate treatment options. There is an increasing demand for cancer biomarkers as a result of increased oncology research, screening programs, and personalized medicine.

Precision oncology adoption accelerates biomarker integration

Precision oncology is revolutionizing cancer therapy by allowing doctors to tailor treatments to the properties of individual tumors. Biomarkers are an essential component of this process, allowing the identification of genetic mutations, protein expression, and biological pathways that affect the response to treatment. As targeted drugs and immunotherapy continue to grow in popularity, there is a need for diagnostic tests to assess their effectiveness. Research hospitals, academic institutions, and pharmaceutical firms are working together to develop a variety of applications of biomarkers in many different forms of cancer.

Advancing molecular diagnostics improves biomarker capabilities

The advancements in molecular diagnostics have improved the speed, precision, and availability of biomarker tests for cancer. Technologies such as next-generation sequencing, PCR, immunohistochemistry, and digital pathology have enabled deeper tumor testing. Diagnostic firms are developing platforms that would streamline testing and enable broader biomarker panels. This helps to promote the use of precision diagnostics as they are now more accessible. With the development of new molecular diagnostic technologies, the significance of biomarker testing in oncology increases.

Key Market Opportunities

Liquid biopsy expansion creates non-invasive testing opportunities

Liquid biopsy is an area with huge potential, as healthcare professionals are looking for less invasive ways of diagnosing, managing, and evaluating treatment responses to cancer. Testing of circulating tumor DNA and other biomarkers helps in repetitive analyses of samples without undergoing the traditional process of tissue biopsy. Improvements in sequencing technologies, assay sensitivity, and computational analysis techniques have made liquid biopsies more effective. The cancer biomarkers market is affected by rising investment from diagnostics and biotech companies developing scalable liquid biopsy solutions. Applications in early cancer diagnosis, disease surveillance, and therapy selection will create new opportunities.

AI-assisted biomarker discovery enhances research efficiency

AI technology presents itself with numerous opportunities through its ability to enhance the discovery process of biomarkers, data interpretation, and clinical trials. The use of AI technology in the analysis of genomics, proteomics, and clinical data can help in the detection of patterns of biomarkers for their diagnostic and therapeutic benefits. Various pharmaceutical companies and research institutions are embracing artificial intelligence technologies to accelerate their oncology discoveries and optimize their clinical trials.

Companion diagnostics growth supports targeted therapy adoption

The development of companion diagnostics provides new possibilities as more personalized cancer therapies depend on the ability to identify patients through the use of biomarkers. Companies producing drugs and diagnostics have joined forces to develop tests to determine whether the therapy is appropriate for the patient. More approvals of targeted therapies and immunotherapies increase the need for diagnostic services. The development of companion diagnostics allows for more effective clinical decisions, while promoting the drug commercialization strategy.

Market Restraints and Challenges

High validation costs limit biomarker commercialization

Factor: Developing and validating cancer biomarkers requires extensive clinical studies, large patient datasets, advanced laboratory infrastructure, and significant research investment.

Impact: High validation costs may also contribute to the delayed commercialization of tests, thereby putting a strain on the budgets of smaller diagnostic companies. Clinical utility, analytical accuracy, and reproducibility must be proven before the widespread implementation of new biomarkers.

Regulatory approval challenges affect market adoption

Factor: Cancer biomarker products must comply with complex regulatory requirements involving clinical evidence, diagnostic accuracy, safety evaluation, and performance validation.

Impact: The lengthy process of approvals might increase the cost of development and even affect the launch of the product by creating uncertainties among the manufacturers. Differences in regulations from one country to another might necessitate further validation testing by manufacturers targeting the global market.

07 Company Analysis

Competitive Landscape

The market competitive landscape is shaped by diagnostic technology providers, life sciences companies, healthcare solution providers, and pharma partners involved in building state-of-the-art biomarker platforms. Firms are concentrating on genomic testing, companion diagnostics, liquid biopsy, AI, and precision oncology solutions. The Cancer Biomarkers Market report suggests that competition in the market is growing due to testing accuracy, expanded biomarker portfolio, and partnerships between diagnostics and therapeutics providers.

Company Name

Overview

Products and Services Relevant to this Market

F. Hoffmann-La Roche Ltd.

Global healthcare company providing diagnostics and pharmaceutical solutions focused on personalized medicine.

Companion diagnostics, immunoassays, molecular diagnostics, oncology biomarker testing platforms.

Thermo Fisher Scientific Inc.

Life sciences company offering analytical technologies and diagnostic solutions for research and healthcare.

Next-generation sequencing, molecular diagnostic systems, genomic analysis platforms.

Abbott Laboratories

Healthcare technology company providing diagnostic and medical solutions globally.

Molecular diagnostics, cancer testing systems, laboratory diagnostic technologies.

QIAGEN N.V.

Molecular diagnostics company specializing in sample preparation and genomic testing solutions.

PCR-based assays, oncology panels, companion diagnostic solutions, molecular testing technologies.

Illumina, Inc.

Genomics company developing sequencing technologies supporting precision medicine applications.

Next-generation sequencing platforms, genomic profiling, cancer biomarker analysis solutions.

Bio-Rad Laboratories, Inc.

Life science and diagnostics company providing research and clinical testing technologies.

Digital PCR, immunoassays, molecular diagnostic tools, biomarker research solutions.

Agilent Technologies, Inc.

Analytical technology company supporting clinical research and pathology applications.

Genomics solutions, pathology platforms, biomarker analysis technologies.

Danaher Corporation

Global science and diagnostics company operating through healthcare technology businesses.

Molecular diagnostics, genomic tools, cancer testing platforms, laboratory solutions.

Siemens Healthineers AG

Medical technology company providing diagnostic imaging and laboratory healthcare solutions.

Diagnostic systems, oncology testing technologies, laboratory diagnostics, healthcare solutions.

Becton, Dickinson and Company

Medical technology company supporting diagnostics, research, and healthcare delivery.

Molecular diagnostics, sample management solutions, laboratory technologies, cancer testing tools.
08 Industry Activity

Recent Developments

July 2026

CareDx completed the acquisition of Naveris for US$160 million upfront plus up to US$100 million in milestone payments, expanding its precision diagnostics portfolio into specialty oncology with the NavDx molecular residual disease (MRD) blood test. NavDx is the only Medicare-covered MRD assay for HPV-positive head and neck and anal cancers, with more than 130,000 tests performed and approximately US$35 million in 2025 revenue.

July 2026

Biocartis and Discovery Life Sciences announced a strategic collaboration to deliver end-to-end precision oncology solutions by combining Discovery Life Sciences' global laboratory network with the Biocartis Idylla Platform. The partnership enables rapid in-house molecular biomarker testing in approximately three hours and expands global clinical trial support through standardized KRAS testing programs across facilities in Germany and the United States.

March 2026

Discovery Life Sciences partnered with Mindpeak to integrate AI-powered digital image analysis into immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) pathology services, enhancing biomarker interpretation accuracy and supporting precision oncology clinical trials through advanced digital pathology workflows.

January 2026

Guardant Health entered a multi-year strategic collaboration with Merck (MSD outside the U.S. and Canada) to support the development and commercialization of oncology therapies using the Guardant Infinity™ Smart platform, including liquid and tissue biopsy assays for clinical trial enrollment and companion diagnostic development.

10 Trust & Transparency

Research Methodology

The market analysis combines proprietary research with secondary data from government agencies, company disclosures, regulatory filings, industry databases and expert interviews. Market estimates are validated through data triangulation, cross-market benchmarking and analyst review.

View Full Research Methodology
11 Questions Answered

Frequently Asked Questions

What challenges affect cancer biomarker commercialization?

Major challenges include high research and validation costs, complex regulatory requirements, lengthy clinical evaluation processes, and the need for consistent analytical and clinical performance evidence.

Why are companion diagnostics important in oncology?

Companion diagnostics help identify patients most likely to benefit from specific therapies, improving treatment selection, supporting regulatory approvals, and enabling pharmaceutical companies to develop targeted oncology treatments.

How is liquid biopsy influencing cancer biomarker development?

Liquid biopsy is enabling minimally invasive cancer detection, treatment monitoring, and disease progression analysis by evaluating circulating tumor DNA and other biomarkers without requiring traditional tissue sampling.

Which cancer type has significant biomarker adoption?

Breast cancer has significant biomarker adoption due to widespread HER-2 testing, hormone receptor analysis, targeted therapy development, and extensive clinical research supporting personalized treatment approaches.

What is driving growth in the Market?

In cancer biomarkers market analysis, growth is driven by rising cancer prevalence, increasing adoption of precision oncology, advancements in molecular diagnostics, expansion of targeted therapies, and growing demand for early detection and personalized treatment strategies.

Access the Full Cancer Biomarkers Market Report

Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.

Download Sample Request Customization
Access the full Cancer Biomarkers Market Report
350 pages PDF & Excel | 2026-07-31
Download Sample Customization